Take action based on the earliest and most subtle physiological indicators and provide your patients with the care they deserve.
Provide your patient with remote feedback and treatment, based on analyzed aggregated data, available 24/7.
Having access to high-resolution V-LAP readings will allow you to diagnose additional cardiac conditions like mitral regurgitation, arrhythmias, diastolic dysfunction and more, using sensitive automated supportive algorithms.
Make better decisions based on artificial intelligence that uses pattern recognition algorithms, to design optimal recovery plans.
The V-LAP maps out heart failure decompensation based on mean left atrial pressure readings, so that physicians can detect impending HF exacerbation and act accordingly. Furthermore, physicians can drill down to daily high-resolution left atrial pressure waveform morphology, receiving input regarding common co-morbidities.
The increase of left atrial pressure is the most specific and earliest sign of impending heart failure exacerbation – long before clinical symptoms occur. V-LAP’s unmet clinical need has been evident for years, and the cardiology profession will benefit greatly from the availability of technology that can provide this valuable indication non-invasively on a daily basis.
Ohio State University Medical Center Division of Cardiovascular Medicine, USA
The V-LAP system detected elevated mean LAP in one of our patients, so we adjusted medications until LAP was reduced to <20mmHg. Normally, we would increase diuretics for a period, but now we'll increase until we see LAP down to less than 16 in this patient. This is really useful!
Cardiologist, Queen Elizabeth Hospital, Birmingham, UK
The V-LAP implantation was smooth and lasted only 6 minutes. We are now able to monitor the patient from home. I have direct access to his daily mean LAP variance and can remotely adjust his dosages when required.
Director of the CardioVascular Center Frankfurt, Germany
Vectorious’ V-LAP holds the potential of great promise for clinical use in Class III heart failure patients; with potential to improve quality of life, reduce mortality, and reduce rates of hospital admissions in this population.
Professor of Cardiovascular Medicine,
Careggi University Hospital, Florence, Italy
Subscribe to get Vectorious' Newsletter with the latest news and clinical updates from the VECTOR-HF study